Psoriasis Clinical Trial

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

Summary

Safety and Efficacy of IDP-118 Lotion to Ultravate® Cream, in the Treatment of Plaque Psoriasis

View Full Description

Full Description

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® Cream, in the Treatment of Plaque Psoriasis

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Male or female, of any race, at least 18 years of age (inclusive).
Freely provides both verbal and written informed consent.
Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA (Body Surface Area) of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation.
Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.
Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA (Investigators Global Assessment) score of 3 or 4. (The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this assessment, if psoriasis is present.)
If female and of childbearing potential, must have a negative urine and serum pregnancy test at the Screening visit and negative urine pregnancy at Baseline visit prior to randomization.
Subject is willing to comply with study instructions and return to the clinic for required visits.

Key Exclusion Criteria:

Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator.
Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator.
Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator.
Is pregnant, nursing an infant, or planning a pregnancy during the study period.
Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently participating in another clinical study with an investigational drug or device.

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

154

Study ID:

NCT02785172

Recruitment Status:

Completed

Sponsor:

Bausch Health Americas, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Valeant Site 12
Fullerton California, 92831, United States
Valeant Site 04
La Mesa California, 91941, United States
Valeant Site 03
San Diego California, 92093, United States
Valeant Site 09
San Diego California, 92093, United States
Valeant Site 05
Lauderdale Lakes Florida, 33313, United States
Valeant Site 02
Miami Florida, 33111, United States
Valeant Site 07
Fridley Minnesota, 55421, United States
Valeant Site 08
Chapel Hill North Carolina, 27514, United States
Valeant Site 06
Columbus Ohio, 43085, United States
Valeant Site 13
Mount Pleasant South Carolina, 29464, United States
Valeant Site 11
Katy Texas, 77449, United States
Valeant Site 10
San Antonio Texas, 78201, United States
Valeant Site 01
Sugar Land Texas, 77479, United States
Valeant Site 14
Salt Lake City Utah, 84103, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

154

Study ID:

NCT02785172

Recruitment Status:

Completed

Sponsor:


Bausch Health Americas, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider